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Cell cycle events have been documented to be associated with several human neurodegenerative diseases. This review focuses on two
diseases – Alzheimer's disease and ataxia telangiectasia – as well as their mouse models. Cell cycle studies have shown that ectopic expression
of cell cycle markers is spatially and regional correlated well with neuronal cell death in both disease conditions. Further evidence of ectopic cell
cycling is found in both human diseases and in its mouse models. These findings suggest that loss of cell cycle control represents a common
pathological root of disease, which underlies the defects in the affected brain tissues in both human and mouse. Loss of cell cycle control is a
unifying hypothesis for inducing neuronal death in CNS. In the disease models we have examined, cell cycle markers appear before the more
well-recognized pathological changes and thus could serve as early stress markers—outcome measures for preclinical trials of potential disease
therapies. As a marker these events could serve as a new criterion in human pathological diagnosis. The evidence to date is compatible with the
requirement for a second “hit” for a neuron to progress cell cycle initiation and DNA replication to death. If this were true, any intervention of
blocking ‘second’ processes might prevent or slow the neuronal cell death in the process of disease. What is not known is whether, in an adult
neuron, the cell cycle event is part of the pathology or rather a desperate attempt of a neuron under stress to protect itself.
© 2006 Elsevier B.V. All rights reserved.Keywords: Alzheimer; Ataxia Telangiectsia; Cell cycle; Neurodegeneration; APP mouse; atm-deficient mouse1. Background
1.1. A normal biological cell cycle
The eukaryotic cell cycle, or cell-division cycle, is a series of
events that lead to cell growth, DNA replication, chromosomal
segregation and the creation of two daughters from an original
mother cell. It is perhaps the most fundamental process of life.
The cell cycle consists of four distinct phases: G1, S, G2 and M
phases. G1 phase is a period of growth and preparation for
division. Among the four phases it is the one with the most
variability in length. During G1 a single cell grows to a point
where it is ready to commit to division. G1 is followed by S
phase in which is the DNA synthetic machinery replicates the
genetic materials in the cell and chromosome number is doubled.⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.10.002The cell then prepares for division in a period known as G2
phase. Finally, during M phase, the chromosomes condense and
move to opposite poles of the cell; the cytoplasm is split and two
daughter cells are created. In cell cycle progression, two critical
molecular classes—cyclins and cyclin-dependent kinases
(CDKs) play key roles in the regulation of progression. The
activation of these proteins varies with the phase of the cycle
according to their own state of phosphorylation. In addition, a
number of cell cycle inhibitors (such as the cyclin D inhibitors
p16 and p27) act together to regulate a cell cycle and help to
control the process by assessing damage and arresting progress
at any of several defined checkpoints.
In the central nervous system (CNS), after young neuroblasts
leave ventricular zone (VZ) or subventricular zone (SVZ), they
become permanently post-mitotic cells. Once they become a
mature neuron, the cell cycle is complete. The mature neuron
will keep this status until the organism dies. The nature of this
permanent exit from the cell cycle is still poorly understood. But
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mature neuronal cell; the cancers that we refer to as “brain”
tumors originate primarily from non-neuronal cells such as
astrocytes, oligodendrocytes, and cells of the meninges. This is
strong evidence that mature CNS neurons do not even try to
divide after maturation. If they could, some neuron-originated
tumor would have formed somewhere in some animal's brain.
Although a small number of neurons destined for hippocampus
and other regions are generated in the adult, their origin is a
remnant of the subventricular zone rather than the result of a
division of a truly postmitotic nerve cell.
1.2. Cell cycle associated cell death in post-mitotic neurons
during development
The concepts of cell division and cell death seemed not only
separate, but polar opposite. The former is a generative process
that favors growth and development while the later is a
destructive event that favors atrophy and loss. A substantial
body of evidence now suggests, however, that the two processes
are intimately related and use many similar mechanisms for
their execution. In the past years, studies have shown the wide
spread applicability of this linkage between cell cycle and cell
death in mature neuronal cells.
Perhaps the first example of this was discovered by
Feddersen et al. [1]. Using genetic engineering of transgenic
mice, they showed that forcing a cell cycle in a mature neuron
could lead to cell death. They took a powerful oncogene, the
SV40 T antigen, and drove its expression in transgenic mice
using a Purkinje cell-specific gene promoter, pcp2. The result
was the induction of cell cycle related neuronal death rather than
division. The functions of T-antigen include the binding of the
endogenous cellular protein known as retinoblastoma (RB) [2].
RB is a nuclear protein that binds to a family of transcription
factors known as the E2F family. If freed from RB, the action of
E2F proteins is to drive the expression of a number of genes that
leads to a cascade of events that initiates cell division and
ensures its progression [3]. In normal quiescent cells, RB is
inactivated through binding to E2F proteins and prevents the
release of E2F family members to initiate the cell cycle, but the
affinity of RB for E2F family members can be modulated
through protein phosphorylation. Higher levels of RB phos-
phorylation lead to release of E2F, which initiates the cell cycle.
In their results, Fedderson et al. found that the transgenic
founders that did indeed express T-antigen revealed an
unexpected ataxic phenotype. The ataxia was caused by a
large amount of cerebellar Purkinje cell death. In these
transgenic mice, they observed that the Purkinje cells swelled
in size and they could be labeled with the DNA precursor—
bromodeoxyuridine (BrdU). But rather than dividing, the BrdU
positive-labeled Purkinje cells died [1]. The suggestion was that
the T-antigen oncogene had successfully initiated a cell cycle
but for some unknown reasons the ‘transformed’ Purkinje cells
could not complete the division.
This suggestion was also put forward to explain the
phenotype of a different mutant mouse that was created in the
following year. Three different labs reported an engineered nullmutation in the mouse retinoblastoma gene [4–6]. All three
found that, in the absence of RB, there were massive amounts of
cell death in the developing embryonic CNS. Further, nerve
cells failed to differentiate to an appropriately age-related stage
in both CNS and PNS before they died. From these early
findings, the concept has arisen that any forced cell division in a
mature neuron is a lethal event.
A few years later, Herrup and Busser [7] extended this
finding through the analysis of two cerebellar mutants where
granule cell death occurs—staggerer (Rorasg) and lurcher
(GridLc). Previous work had shown that granule cell loss was
an indirect consequence of their failure to establish (staggerer)
or maintain (lurcher) target contact. The direct destructive
effects of the mutations, however, were on the granule cell
target, the Purkinje cell. In both mutants, cerebellar granules
cells rapidly die. Herrup and Busser showed that their deaths
were accompanied by the re-expression of cell cycle proteins
and incorporation of BrdU. These findings were evidence that,
even in the natural setting of target-related cell death, post-
mitotic neuronal cells that enter into an unscheduled cell cycle
die.
Recently, the principal of cell cycling as a corollary of the
cell death process has been extended further. Chen et al. [8]
have shown that in mice lacking the cell cycle inhibitor,
p19Ink4d, there is a severe postnatal loss of hair cells. The death
is cell cycle related as BrdU is incorporated into the normally
post-mitotic cells.
Tissue culture model systems have also been developed and
have provided some of the most detailed evidence establishing a
linkage between cell cycle and cell death. Some of these data
come from analyses of cell lines such as PC12 cells [9–12].
Using pharmacological approaches, Greene and colleagues
have shown that drugs whose action blocks cell cycle advances
are efficient at preventing the death of PC12 cells as well as
sympathetic neurons [9–11,13]. Molecular genetic approaches
have also been applied. Park et al. [11] used dominant negative
forms of the Cdk4 and Cdk6 proteins to show that the cell death
process induced by camptothecin are effectively blocked by
following treatment with the G1/S blockers, such as deferox-
amine, mimosine, as well as by the CDK inhibitors flavopiridol
and olomoucine. The same authors have also shown that
neurons treated with DNA damaging agents such as UV
irradiation or camptothecin (a topoisomerase inhibitor) also
require cyclin D and Cdk4/6 activity to induce neuronal death
[14]. More detailed mechanistic data on the process was
provided when it was shown that by blocking the cell cycle with
cyclin-dependent kinase inhibition they could block neuronal
cell death in culture [10,11,15]. These in vitro models are
significant since many of them provide direct experimental
evidence that, rather than merely being associated with cell
death, an ectopic cell division is both necessary and sufficient to
produce the death of neurons.
Taken together, these findings suggest that post-mitotic
neurons are in a state of terminal differentiation and incapable of
undergoing cell division. Nevertheless, they might retain certain
elements of the cell cycle and have the capability of reactivating
additional aspects of the replication mechanism when under
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back into the cell cycle are lethal rather than mitogenic for the
neuron.
2. Cell cycle events in neurodegenerative diseases and their
mouse models
Over the past decades, there has been a growing body of
evidence of cell cycle events associated with the progression of
neuronal cell death. It seems only logical, therefore, to transfer
this theme from developmental times in mutants or engineered
lines of transgenic mouse to the field of the neuronal cell death
in neurodegenerative diseases. We asked whether similar
concepts and mechanisms apply to the occurrence of neuronal
cell death in neurodegenerative diseases. And indeed, in recent
years, several neurodegenerative diseases have been found
associated with an apparent induction of a cell cycle in the brain
areas where neurons are significantly lost in the disease
conditions. Several laboratories have provided evidence for
ectopic elevation and re-expression of cell cycle proteins in
Alzheimer disease, Parkinson disease, amyotrophic lateral
sclerosis, stroke ataxia–telangiectasia and some forms of
encephalitis [16–18]. In the current review, we will discuss
the relationship of loss of cell cycle control and neuronal cell
death in two neurodegenerative diseases that we have studied
intensively—Alzheimer's disease [19–22] and ataxia telan-
giectasia [23]. Both diseases have well-established mouse
models and we shall consider these as well.
2.1. The progression of Alzheimer’s disease
Alzheimer's disease (AD) is the most common form of late-
life dementia. It presents with a spectrum of significant clinical
symptom that include deficits in the ability to form recent
memories, executive dysfunction, impairment of cognition and
other abnormal behavioral symptoms. Neuropathological find-
ings in the AD brain are characterized by abnormal deposits of
Aβ peptide and neurofibrillary tangles. The former consists of
an abnormal cleavage product (Aβ) of a membrane protein
known as APP; the latter consists of aggregates of hyperpho-
sphorylated microtubule associated protein—tau. The density
of neuronal cells (cell bodies and synapses) is significantly
reduced in the frontal, entorhinal, hippocampal cortex and other
limbic areas. In addition, certain sub-cortical neurons are
involved in substantial amounts of neurodegeneration [24]. The
loss of nerve cells in AD is regionally variable with severe
losses observed in the hippocampus, frontal, entorhinal cortex,
as well as in the basal nucleus of Meynert [25], the locus
coeruleus [26,27] and the dorsal raphe [26,28].
There are two basic classifications of AD: familial AD
(FAD) and late onset AD (LOAD). FAD has a relatively early
age of onset, typically before the age of 65. It is relatively rare
(5% of the total number of cases) and is nearly always caused by
a single autosomal dominant mutation (PS1 and, more rarely,
APP or PS2) with near 100% penetrance. It is a prominently
studied form of Alzheimer's disease and the basis of most of the
mouse modeling work. Despite this, 95% of the patients withAD suffer from the sporadic LOAD form of Alzheimer's, the
biological basis of which is unknown. The onset of the LOAD is
typically after the age of 65. As of this date, tremendous
numbers of studies have been done with the goal of determining
the biochemical pathways leading to the Aβ deposits and
neurofibrillary tangles. For reviews of this topic the reader is
referred to several recent references [29,30]. Yet the puzzle in
the field has always been that despite the depth in which we
understand the biochemical pathology (the Aβ plaques and the
tangles of tau), the path that leads from these deposits to the
regionally variable neuronal loss remains unknown.
Our laboratory has attempted to address this puzzle by
focusing on the increasing evidence that the activation of cell
cycle components is associated with cell death in the AD brain.
We and others, have shown a close association between the
neuronal cell death in AD and cellular processes that normally
only occur during a mitotic cell cycle. Beginning with immuno-
cytochemical evidence, many studies have reported that a wide
range of cell cycle proteins, including cell cycle inhibitors, are
elevated in neurons in at-risk regions of late stage of AD patients
(Fig. 1A), but not in age-matched controls [19,31–39]. The cell
cycle proteins whose levels have been reported to increase in AD
include cyclin D, E [19,38,40], cdk4 ([19], PCNA [19,37],
cyclin B[19], cdc2 [41–43] and Ki67 [37,38]). In addition, a
number of studies have shown that several Cdk inhibitors are
also present. These include p16 [3,32,44,45], p21 [45] and p105
[46]. Appearance of these cell cycle proteins is usually found
only in actively mitotic cycling cells.
Yang et al. [21] have also reported that expression of cell
cycle proteins is elevated in the at-risk areas during the early
stages of neurodegeneration—a stage often referred to as mild
cognition impairment (MCI). This is important as MCI is a term
used to describe a subtle age-associated decline of human
mental ability. Although there are controversies concerning the
precise definition, a number of studies offer evidence that a high
percentage of individuals diagnosed with MCI will progress to
AD within 3–5 years [47]. Yang et al. [21] showed that in the
brains of individuals who died with MCI the percentage of cell
cycle positive neurons is nearly identical to that found in
individuals who died with late stage AD. These findings suggest
that neuronal death is related to cell cycle re-entry throughout
the entire period of disease rather than a phenomenon that
occurs only during the final stages preceding death.
A persistent and important question has been raised by these
studies: does the immunocytochemical appearance of cell cycle
proteins have any functional meaning in terms of actual cell
cycle progression or is their appearance merely a reflection of a
more global and non-specific dysregulation of protein synthesis?
We have addressed this question by using fluorescent in situ
hybridization (FISH) as a direct measure of DNA replication in
the neurons of AD. Our lab [20] performed FISH using either
large genomic probes to unique specific loci in the human
genome or small probes to the highly repetitive DNA of the
centromere of specific chromosomes. The FISH technique
allows us to examine the numbers of copies of individual loci in
neuronal nuclei. We found that, in AD brain, a significant
fraction of the hippocampal pyramidal and basal forebrain
Fig. 1. Cell cycle events associated with degenerating neuronal cells in AD and A–T. (A) A hippocampal neuron from an AD patient specimen shows cyclin B positive
immunostaining (from Yang et al. [21]). (B) PCNA expressed in the cerebellar Purkinje cells of diagnosed A–T patient. (C) In cortical neurons of the transgenic R1.40
mouse, the cell cycle marker, cyclin A, is re-expressed (arrows). (D) PCNA is expressed in the cerebellar Purkinje cells of atm-deficient mouse. (E) FISH analysis shows
four bright hybridization signals from a unique locus in the mouse genome, indicating that DNA replication has occurred in the hippocampal neuron of transgenic R1.40
mouse (from Yang et al. [22]). (F) DNA replication also can be found in the Purkinje cells of the atm-deficient mouse (from Yang et al. [23]).
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on separate genetic loci with different probes from three different
individual chromosomes. This is a direct indication that DNA
replication has occurred in the neuronal cells. No such anomalies
were found in unaffected regions of the AD brain or in non-
demented age-matched controls. These findings further prove
that the ectopic expression of cell cycle proteins is sufficiently
coordinated that a true cell cycle has been attempted and
proceeded, most of the way through S-phase. Curiously, the cells
are largely unable to progress further to complete their division.
No cellular event of mitosis (M-phase) is found, not even the
beginning of chromosome condensation. At the time this study
was published, we proposed that cell cycling was initiated in at-
risk neurons in AD and that the ultimate death of the nerve cells
was attributable to the genetic imbalance caused by the nearly
complete replication of the genome.2.2. Mouse Models of Alzheimer’s disease
Many different transgenic mouse models have been gene-
rated that recreate the genetic changes in found in familial AD
[48–52]. Transgenic mice expressing mutant human APP genes
often exhibit an age-related development of diffuse and neuritic
plaques, with plaque severity burdens equivalent to those found
in advanced cases of AD. These APP transgenic mouse models
have been used and proven to be a valuable resource in the
exploration and design of disease therapies [53]. In addition, the
AD mice show microglial activation, astrocytosis, and changes
in neuronal cytoskeletal proteins including tau [50,54,55]. Many
of these models have also been shown to have significant
memory deficits [49–51]. Despite these findings and their
similarities to the human disease conditions, none of the mouse
models has yet been shown to develop the typical neurofibrillary
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bodies been reported (for review see reference [56]). Recently
the LeFerla lab has been able to create a more complete
pathological picture by incorporating three transgenes into a
single mouse [51,57]. These animals have provided valuable
insights, but the fact remains that they are not true models of AD
as their genetics is complex and not representative of even the
more rare forms of FAD.
It has been a curious observation that in virtually all AD
mouse models, even those with a close genetic mimicry of FAD,
the loss of neurons is either non-existent or relatively mild. The
reason for the discrepancy between the human and mouse
neurodegenerative phenotype is unclear. As cited above, there
are a large and growing number of conditions in mouse in which
neuronal cell death is associated with re-entrance into a lethal
cell cycle. These include the retinoblastoma deficient mouse
[4–6], cerebellar target-related cell death [58], oncogene
expression in maturing neurons [1], oxidative stress as
suggested by the harlequin mouse [59], as well as MCA
occlusion models of stroke [17] and the SOD-1 mouse model of
amyotrophic lateral sclerosis [60,61]. These in vivo studies,
combined with elegant studies in cell culture [62,63] strongly
implicate the initiation of cell cycling as a causative factor in the
death of these neurons.
Because of this close association between the aberrant
neuronal cell cycle and neuronal degeneration in several
neurodegenerative disorders, it occurred to us to ask the
reasonable question of whether the cell cycle phenotype was
preserved in the neurons of the AD mouse model, even in the
absence of overt neuronal degeneration. This indeed proved to
be the case. Yang et al. reported that abnormal cell cycle
processes have begun in the appropriate neurons in three
different transgenic models of AD—R1.40, Tg2576 (or
Tg2576/PS1) and APP23 [22]. Both the ectopic expression of
cell cycle proteins (Fig. 1C) and the occurrence of the true DNA
replication (Fig. 1E) have been documented in these three
transgenic lines. Thus these normally post-mitotic neuronal
cells have attempted a cell cycle process that strongly resembles
a mitotic cell division. With a more detailed study of when the
initiation of cell cycle events occurs in the transgenic R1.40
line, we have shown cell cycle alterations are evident at
6 months of age. This is well before the first Aβ deposits that
are not found in these animals until after the mouse is 1 yr old.
Furthermore, the neuronal cell cycle activity precedes the
appearance of CD45+ activated microglia, and it occurs in an
anatomical pattern that recapitulates the selective neuronal
vulnerability observed in AD. This suggests that the ectopic
initiation of cell cycle processes in neurons is an early sign of
neuronal distress in both human and mouse AD. The relative
timing of cell cycle appearance in the R1.40 mouse suggests
that neither the activated microglia nor the amyloid plaques
themselves are necessary to initiate the pathogenic events in
AD. The authors reported also that the expression level of cell
cycle proteins vary among the different cortical regions of the
transgenic brain. In the sub-cortical structures, cell cycle
proteins are re-expressed in the neurons of the dorsal raphe
and the locus coeruleus, but not in the substantial nigra, whichwas considered not involved in pathologic changes in AD. This
corresponds well with findings in Alzheimer's disease.
Curiously, the cholinergic neurons in the mouse basal forebrain
are cell-cycle negative, yet the neuronal loss in this cell group is
severe in AD. It is remarkable that the CCEs in mouse are
correct in their anatomical appearance relative to the human
disease. The markers appear most strongly in the hippocampal
formation (including entorhinal cortex) and in frontal cortical
regions. Further, just as in the human disease the adrenergic
neurons of the locus coeruleus and the serotonergic neurons of
the dorsal raphe are also affected by the abnormalities in cell
cycle regulation.
The study illustrates that cell cycle events are correlated with
neuronal death in three individual different mouse models of
human Alzheimer's disease just as in the human condition itself.
We must face the fact, however, that none of the three transgenic
mouse lines has any significant loss of neuronal cells. This
raises an unexpected conclusion: the cell cycle events may be a
necessary first step in the neuronal cell death process in AD, but
they are not sufficient induce cell death. This means the
initiation of the cell cycle, including DNA replication, can be
followed by many months during which the aneuploid neurons
persist in what we can assume is a near functional state. This is
implied by the fact that the R1.40 animals have mild behavioral
abnormalities [56]. This suggests that the cell cycle induced
neuronal cell neurodegeneration is a slow prosecution of a
complex cell death program. In retrospect this is entirely
consistent with the calculations of Busser et al. [19] and Yang et
al. [20] in their studies of human Alzheimer disease brains.
2.3. Human Ataxia Telangiectasia
Ataxia telangiectasia (A–T) is an autosomal recessive
disorder characterized by cerebellar ataxia, progressing to
substantial loss of motor function. On pathological examination
cerebellar Purkinje and granule cell degeneration is noted [64]
as well as neuronal loss in striatum and substantia nigra at the
more advanced stages of the disease [65–68]. Other observed
phenotypes in this complex disorder include retinal telangiec-
tasia, immunodeficiency, radiosensitivity, infertility, predisposi-
tion to malignancies and progressive neuronal degeneration
[64,69,70]. In A–T patients, the extent of the Purkinje cell loss
is correlated with the severity of the clinical phenotype.
A disease gene has been identified, Ataxia–telangiectasia
mutated (ATM). The protein encoded by this gene is a 370 kDa
serine/threonine kinase. The primary sequence shows analogy
with the catalytic subunit of phosphatidyl-inositol-3-kinase
(PI3K) [71–75]. Many of the substrates of ATM are known to
be involved in DNA double strand break detection and cell
cycle arrest [76–80]. ATM is a central player in an elaborate
network of proteins that responds to the presence of DNA
double strand breaks and, in the aggregate, arrest the cell cycle
until the damage to the genome can be repaired. Because the full
A–T syndrome includes defects in cell cycle regulation plus
neuronal degeneration, we were interested in determining
whether the loss of neurons was in any way related to the cell
cycle control defects.
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of ATM gene in A–T has been extensively studied from the
standpoints of the immune deficiency and tumor susceptibility.
Evidence from skin fibroblasts, myeloid cells and other cells
cultured from A–T patients (or atm−/− mice) points to the
existence of significant deficits in cell cycle control. We
hypothesized that the neurological phenotype in A–T disease
could have as one of its roots causes a neuron-specific failure of
ATM-dependent cell cycle control. In 2005, Yang and Herrup
[23] reported their findings on autopsy specimens from
cerebella of individuals diagnosed with A–T. In keeping with
our hypothesis, 10–20% of the post-mitotic cerebellar Purkinje
and granule cells had detectable levels of PCNA, cyclin A and
cyclin B in their nuclei and/or cytoplasm using immunohis-
tochemistry (Fig. 1B). All regions of the A–T brain that have
been identified with neuronal cell loss (basal ganglia, striatum),
had evidence of ectopic cell cycle proteins in neuronal cell
bodies. Little or no staining was found in age-matched control
samples, and there was no immunocytochemical signal from
regions of the brain that are unaffected in A–T. This evidence
points to a situation in which, despite their supposedly post-
mitotic status, mature Purkinje cells have re-initiated a lethal
cell cycle, suggesting that cell cycle events are clearly
associated with neurons at risk for death in A–T. We propose
that the pathogenic mechanism that drives the loss of Purkinje
and granule cells in A–T is similar in at least some of its core
components to other disorders such as Alzheimer's disease.
This tight correlation argues that the immunolabeled proteins
are closely tied to the neurodegeneration itself and mark a
neuron under stress and at high risk for death.
2.4. Ataxia telangiectasia mouse model—atm-deficiency mouse
Mouse models of A–T have been created in different
laboratories [81–85] and have been closely studied for hints to
the biological basis of the human disease. Engineered mutations
in the mouse ATM homolog (atm−/−) accurately mimic most of
the non-CNS features of human A–T [81,82,84–86]; the
findings in the nervous system have been less consistent. This is
because, in the mouse atm−/− CNS, there is no significant loss
of cerebellar Purkinje cells. Dislocated and abnormally
differentiated Purkinje cells and other neurological defects
including behavioral abnormalities and altered electrophysiol-
ogy, have been seen in these mice [83,85]. Eilam et al. [87,88]
reported the reduction of tyrosine hydroxylase-positive nigro-
striatal neurons and dopamine transporter in atm −/− mice, but
biochemical evidence from Mount et al. [89] in the same animal
model raises the scepter of additional complexities. We know
that ATM responds to DNA damage ([90–93]. We also know
that, through its targeting of p53 for phosphorylation, ATM
protein plays a role in neuronal death [94]. Further, mutations in
NBS1 and hypomorphic mutations of the MRE11 gene are
associated with human neurological defect—Nijimegen break-
age syndrome and ataxia–telangiectasia-like disorder, respec-
tively [95–97]. Nbs1 and Mre11 associate with Rad50 to form a
larger molecular structure known as the MRN complex. This
complex is both a target and a direct inducer of the ATM kinaseand it plays a role in DNA double strand break processing and
checkpoint signaling.
All of this information, however, has been gained though the
study of cultured cell lines. Understanding the role of ATM in
the context of the post-mitotic neuron of the central nervous
system remains a great challenge. In the study by Yang and
Herrup [23] , the authors showed elevated cell cycle proteins
(cyclin A and PCNA) in both mouse Purkinje cells (Fig. 1D)
and neurons of the striatum, just as they had found in the human
brain. They confirmed that the immunostaining represented a
coordinated cell division program by using the patterns of FISH
labeling to demonstrate that significant DNA replication had
occurred in these ‘post-mitotic’ Purkinje cells (Fig. 1F). Thus a
cell cycle process has begun in these cells and proceeded
through most or all of S phase. As in the human A–T situation,
this cell cycle activity is associated with the degenerative
process of neurons. The observations suggest that failure of cell
cycle regulation is a unifying feature of the disease process in all
affected A–T tissues, explaining not only the radiation
sensitivity and cancer predisposition in A–T, but also the
neurodegeneration. The atm mouse model shows that loss of
cell cycle control occurs in the atmmice at levels comparable to
those found in human A–T. The FISH data reveal that a true cell
cycle has been initiated since significant genomic DNA
replication occurs in the mouse atm−/− Purkinje cells. The
RB-deficient mouse, the granule cell death in lurcher and
staggerer, and the results of neuronal tissue culture experiments
all show that initiating a cell-cycle is a lethal event; for a neuron,
loss of cell cycle control results in cell death, not tumorigenesis.
Abortive cell cycle re-entry is tightly correlated with the
degeneration of Purkinje cells in individuals diagnosed with
ataxia–telangiectasia and its mouse model. This suggests that
mature Purkinje cells can re-initiate a lethal cell cycle in both
mouse and man and further suggests that the loss of Purkinje
and granule cells in A–T may share a common pathogenic
mechanism with other neurodegenerative disorders.
2.5. Abnormal cell cycle and other neurodegenerative diseases
Activation of cell cycle machinery has also observed in
vulnerable regions in several other neurodegenerative disorders.
Postmortem brain tissue studies of stroke or ischemia have
revealed evidence for the reexpression of cell cycle proteins such
as PCNA, cyclin D and GADD34 [98,99]. The appearance of
these cell cycle proteins at very early times after middle cerebral
artery occlusion (MCAO) strongly suggested that the initiation
of a cell cycle is an early event in the process leading to cell
death. Cell cycle markers have also been detected in the brain of
patients diagnosed with Parkinson disease [100] and amyo-
trophic lateral sclerosis [18] . Ectopically expressed cell cycle
proteins have also been reported in frontal–temporal dementia,
in Niemann–Pick disease, Pick's disease, and in progressive
supranuclear palsy [101]. Evidence of cell cycle related cell
death has also been observed in the experimental in vivo model
of Parkinson's disease [102] , as well as recent reported in the
mousemodels of both amyotrophic lateral sclerosis [18,103] and
the related SOD-1 transgenic mouse model [104].
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The atm mouse highlights the same problem that we first
ran across with the AD mouse models: cell cycle positive
neurons (with elevated expression of cell cycle proteins and
supernumerary copies of several DNA loci) can and do
survive for months. Neither the APP transgenic mouse models
of AD nor the atm-deficient mouse suffer any significant loss
of neuronal cell bodies even many months after these cells
have initiated a cell cycle and replicated their DNA. Yet in
human AD or AT disease the loss of neurons is profound (and
the neurological phenotype is proportionately more severe).
The reason for the discrepancy between the human and mouse
neurodegenerative phenotype is unclear. How can these
findings are synthesized into a single view of the life and
death of the neuron.
We know that the appearance of aberrant neuronal cell cycle
is closely related to the findings of neuronal degeneration in
human brain. In the mouse, cell cycle re-entrance consistently
occurs in three different APP mouse models of AD and in atm-
deficient mice. In the mouse, the cell cycle events are found
early in the disease process, before significant pathologic
findings (months before the plaques in APP transgenics; during
the Purkinje cell dendritic development is complete in A–T).
Yet studies of both AD and atm/ mouse models showed that
neurons do not die even after reentry into the cell cycle. The
discordance might suggest that a somewhat different perspec-
tive of the human situation might be called for.Fig. 2. Cell cycle associated cell death in neuronal cells. (A) During the neurogenic p
ventricular zone, neurons become permanently post-mitotic and begin their migrati
neurons completes its morphological and biochemical differentiation program. (D)
results in the neuron re-entering a cell cycle followed by death within hours. (E) In a m
cycle will lead to a state which is permissive, but not sufficient to lead to neuronal d
breaks) is needed to push the process of cell death in the adult neuron.There would seem to be two basic interpretations of these
observations. The first is that the cell cycle events themselves
are necessary, but not sufficient to induce the death of adult
CNS neurons. Perhaps, just as in cancer, a ‘second hit’ is
needed [105]. One such triggering event could be hypoxia–
ischemia, or reactive oxidative stress, as three recent papers
implicate cell cycle events in the neuronal death following
hypoxia–ischemia in rodents [106,107]. In addition, recent
studies in transgenic mice producing wild-type human tau, in
the absence of endogenous mouse tau, have documented the
formation of neurofibrillary tangles and neuronal cell death
associated with altered cell cycle events [108]. The suggestion
is that different tau isoforms or tau expression patterns are
potential triggering events in a complex web of cytological
interactions. In keeping with this proposal, the transgenic lines
with altered tau homeostasis have more reliably been
associated with neuronal cell death than other transgenic
models.
The cell cycle events are correlated with neuronal cell stress
in the adult CNS, but correlation is not proof of causality.
Another intriguing possibility is that, for unknown reasons, the
CCEs we observe are actually protective responses of a neuron
under stress, and that much as in certain developmental
situations [109] the neuron benefits from having multiple
copies of each allele. The end result of a neuronal cell cycle is
the death of the cells, but the long times required between
initiation of the cycle and death suggests that in vivo there
are other factors that must be involved in the death process.eriod cells divide rapidly in the region of the ventricular zone. (B) After leaving
on to their final adult location. (C) During and after migration is complete the
Before they have reached a certain state, any interruption of cell cycle control
ature neuron, any mitotic stress or stimulus that induces neuron reenter into a cell
eath. (F) We hypothesize that a second “hit” (oxidative, inflammation and DNA
464 Y. Yang, K. Herrup / Biochimica et Biophysica Acta 1772 (2007) 457–466It is noteworthy that in a wide variety of different neuro-
degenerative conditions, these events are reliable and early
markers of neuronal distress. Cell cycle is a permissive event for
vulnerable neuronal cells, but the final death of the neuron likely
requires a second hit. Several possible stimuli such as chronic
inflammation, hypoxia and/or DNA damage, oxidative stress
may serve this function and force neuronal cells that are already
under cell cycle stress to commit to death in vivo and in
experimental in vitro systems. This second event is an
environmental insult of either chemical or physical nature to
further affect on stressed cycling cell (Fig. 2: the scheme of
hypothesis).
If we could learn more details of the underlying biology of
the forward reaction we will learn enough about the ‘kinetics’ of
the process that we can provide conditions that favor the reverse
reaction in both mouse and human. It would offer prevention
strategies of potential clinical importance.
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